HERE IS THE NEWS I AM WAITING FOR; HemoGenix goes public in a reverse merger - buying VODG for $3 a share.
WHY? 1. VODG is a great fit and compliments HemoGenix. 2. VODG has awesome patents and products that HemoGenix is having first hand experience with, and capabilities taking them and running with them. 3. They obviously are having a growing, more serious relationship and get along. 4. Cost of going public and providing an exit strategy for HemoGenix shareholders is icing on the cake.
Most here realize that sales are needed before Vitro breaks out,and this report strongly suggests we are well positioned and competitive in the marketplace.
I especially like that Dr.Musick specifically calls out our competitors by name and cites Vitro's product superiority!
Dr. Jim Musick, Ph.D., Vitro’s President and CEO and the inventor of the VitroGrow™ Brand of stem cell media, said, “We are pleased to report the latest findings of our ongoing studies comparing VitroGrow™ MSC media to our competitor’s products. We are especially pleased that our media outperforms our competitors at both reduced oxygen levels and the oxygen levels of air (~ 20%). While the former more accurately reflects the in-vivo environment, many researchers perform initial studies at ambient oxygen levels, where our media results in substantial increase in MSC growth rate compared to media provided by our competitors. Our media also supports growth of MSCs from human, mouse and rat species thus expanding its application to stem cell research. We are preparing a white paper describing these results in much greater detail.”